Search for content, post, videos

Cytovation announces private fundraising round of NOK 20m

cytovation

The financing was led by a group of private investors in Norway and the company will use these funds to advance lead product CyPep-1 into a Phase I clinical trial.

Cytovation is developing CyPep-1, a peptide consisting of 27 amino acids that selectively targets cutaneous warts through the destruction of the cell membrane and creating an immune response through the release of antigens. These funds will enable Cytovation to conduct pre-clinical toxicology studies and GMP manufacturing of CyPep-1 as a topical cream for the treatment of warts caused by the human papilloma virus (HPV).

“We have been encouraged by the continuing support of our new and existing investors. These funds will allow us to move through toxicology studies and formulation towards our planned Phase I clinical trial for CyPep-1 with initial results expected during 2018,” said Cytovation’s CEO, Kjell Inge Arnevig.

Leave a Reply

Your email address will not be published. Required fields are marked *

five × five =